jRCT2031240430招募中不适用
A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of anti-GD2 Antibody Drug Conjugate M3554 in Participants with Advanced Solid Tumors
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Escalation A: participants with documented histopathological diagnosis of locally advanced or metastatic STS with unresectable disease that has progressed after at least one prior line of systemic therapy for the metastatic setting including anthracyclines. Previous trabectidin, eribulin, pazopanib or any other drug approved for the different STS subtypes in second line (2L) or beyond will not be required for enrollment but will be allowed (for example [e.g] trabectedin, pazopanib for leiomyosarcoma (LMS); ifosfamide, gemcitabine-based combinations, trabectedin, eribulin, pazopanib for liposarcoma (LPS); trabectedin, gemcitabine, and docetaxel, pazopanib for undifferentiated pleomorphic sarcoma [UPS]). Participants with resectable locally advanced or metastatic disease, who had surgery before study entry will be allowed in the trial if there is residual disease after surgery and if the surgery was performed at least 4 weeks before first dose of study intervention.
- •Escalation B: participants with documented histopathological diagnosis of glioblastoma, IDH-wildtype, who have progressed after ONLY one prior line of therapy (including radiotherapy +/- temozolomide, depending on the O^6-methylguanine-DNA methyltransferase [MGMT] status) and relapsing at least 3 months after the end of the radiotherapy treatment.
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) below or equal to 1
- •Participants with adequate hematologic, hepatic and renal function as defined in protocol
- •Other protocol defined inclusion criteria could apply
排除标准
- •Participant has a history of malignancy other than STS or glioblastoma (depending on the escalation/expansion cohort) within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hypertropia, or malignancy that in the opinion of the Investigator, is considered cured with minimal risk of recurrence within 3 years).
- •STS only: Participants with history of brain metastasis, leptomeningeal metastasis, or participants with spinal cord compression
- •Other protocol defined exclusion criteria could apply
研究者
相似试验
已完成
1 期
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid TumorsOsteosarcomaMelanomaSarcomaNeuroblastomaNCT02107963National Cancer Institute (NCI)15
已完成
2 期
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With NeuroblastomaNeuroblastomaNCT00072358Memorial Sloan Kettering Cancer Center291
进行中（未招募）
1 期
EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structuresCTIS2023-506823-28-00Institut Bergonie120
已完成
1 期
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and MelanomaOsteosarcomaMelanomaEwing SarcomaNeuroblastomaNCT00743496St. Jude Children's Research Hospital50
已完成
2 期
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous TreatmentNeuroblastomaNCT00089258Memorial Sloan Kettering Cancer Center74